Post-neoadjuvant strategies in breast cancer: from risk assessment to treatment escalation

Neoadjuvant treatment for early breast cancer (EBC) has been historically proposed to enable breast-conserving surgery in stage II-III, in particular for triple negative and HER2-positive EBC, although a recently published meta-analysis suggests that this strategy could fail in reducing the mastectomy rate [1-3]. Interestingly, in the last few years, this setting has become an ideal scenario for drug development and biomarker discovery, with an in vivo evaluation of tumor dynamic response as early outcome [4-6].

Source: Cancer Treatment Reviews - October 30, 2018 Category: Cancer & Oncology Authors: Giacomo Pelizzari, Lorenzo Gerratana, Debora Basile, Valentina Fanotto, Michele Bartoletti, Alessia Liguori, Caterina Fontanella, Simon Spazzapan, Fabio Puglisi Tags: Anti-Tumour Treatment Source Type: research